EP1019065A4 - Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications - Google Patents
Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applicationsInfo
- Publication number
- EP1019065A4 EP1019065A4 EP98947089A EP98947089A EP1019065A4 EP 1019065 A4 EP1019065 A4 EP 1019065A4 EP 98947089 A EP98947089 A EP 98947089A EP 98947089 A EP98947089 A EP 98947089A EP 1019065 A4 EP1019065 A4 EP 1019065A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- kits
- formulation
- compositions
- applications
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5916097P | 1997-09-17 | 1997-09-17 | |
US59160P | 1997-09-17 | ||
US09/093,972 US6825174B2 (en) | 1995-06-07 | 1998-06-09 | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
US93972 | 1998-06-09 | ||
PCT/US1998/019419 WO1999013886A1 (en) | 1997-09-17 | 1998-09-17 | Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1019065A1 EP1019065A1 (en) | 2000-07-19 |
EP1019065A4 true EP1019065A4 (en) | 2002-02-20 |
Family
ID=26738426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98947089A Withdrawn EP1019065A4 (en) | 1997-09-17 | 1998-09-17 | Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1019065A4 (en) |
JP (1) | JP2003517428A (en) |
KR (1) | KR20010030622A (en) |
AU (1) | AU752531B2 (en) |
BR (1) | BR9812650A (en) |
CA (1) | CA2304312A1 (en) |
IL (1) | IL135140A0 (en) |
WO (1) | WO1999013886A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030165888A1 (en) | 2001-07-18 | 2003-09-04 | Brown Bob D. | Oligonucleotide probes and primers comprising universal bases for diagnostic purposes |
US6518017B1 (en) | 1997-10-02 | 2003-02-11 | Oasis Biosciences Incorporated | Combinatorial antisense library |
CA2235420A1 (en) | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
US20040043948A1 (en) * | 2001-09-24 | 2004-03-04 | Isis Pharmaceuticals Inc. | Antisense modulation of interleukin 8 expression |
US8273866B2 (en) * | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US20030060438A1 (en) * | 2000-08-18 | 2003-03-27 | Henry James L. | Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof |
US20050014172A1 (en) | 2002-02-20 | 2005-01-20 | Ivan Richards | RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA) |
US6656732B1 (en) | 2001-05-18 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Antisense inhibition of src-c expression |
EP1432724A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | Rna interference mediated inhibition of map kinase genes |
US8232383B2 (en) | 2002-02-20 | 2012-07-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20090099117A1 (en) | 2002-02-20 | 2009-04-16 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7683166B2 (en) | 2002-02-20 | 2010-03-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
AU2003268032A1 (en) * | 2002-07-29 | 2004-02-16 | Epigenesis Pharmaceuticals, Inc. | Composition and methods for treatment and screening |
US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2004035759A2 (en) * | 2002-10-18 | 2004-04-29 | Genta Salus Llc | Inhibitory oligonucleotides targeted to matrix metalloproteinase-9 |
WO2004043353A2 (en) * | 2002-11-06 | 2004-05-27 | Ludwig Institute For Cancer Research | Compositions and methods for treating acute myeloid leukemia |
CA2421086A1 (en) * | 2003-02-28 | 2004-08-28 | Institut Pasteur | Chicken rna polymerase i promoter and its use |
US7399853B2 (en) * | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
WO2006045202A1 (en) | 2004-10-29 | 2006-05-04 | Topigen Pharmaceuticals Inc. | Antisense oligonucleotides for treating allergy and neoplastic cell proliferation |
EP2316941A3 (en) * | 2005-02-25 | 2012-03-14 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to IL-4R alpha |
CN102036689B (en) | 2008-03-17 | 2014-08-06 | 得克萨斯系统大学董事会 | Identification of micro-RNAs involved in neuromuscular synapse maintenance and regeneration |
KR101801407B1 (en) * | 2009-07-24 | 2017-11-24 | 큐알엔에이, 인크. | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
WO2015130832A1 (en) * | 2014-02-25 | 2015-09-03 | The Regents Of The University Of California | Agents for enhancement of production of biofuel precursors in microalgae |
JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
US10350307B2 (en) * | 2017-09-18 | 2019-07-16 | General Electric Company | In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides |
CN112673103A (en) | 2018-08-13 | 2021-04-16 | 阿尔尼拉姆医药品有限公司 | Hepatitis B Virus (HBV) dsRNA agent compositions and methods of use thereof |
CN110527630B (en) * | 2019-05-24 | 2021-04-20 | 浙江工业大学 | Aleurites lutescens mutant strain bred by ARTP mutagenesis technology and application thereof |
AU2022297513A1 (en) * | 2021-06-23 | 2024-01-18 | Enclear Therapies, Inc. | Method of regulating gene expression |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040266A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for asthma |
WO1996040162A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for lung diseases using antisense oligonucleotides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9210273D0 (en) * | 1992-05-13 | 1992-07-01 | Ici Plc | Dna |
US6025339A (en) * | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
-
1998
- 1998-09-17 CA CA002304312A patent/CA2304312A1/en not_active Abandoned
- 1998-09-17 EP EP98947089A patent/EP1019065A4/en not_active Withdrawn
- 1998-09-17 BR BR9812650-4A patent/BR9812650A/en not_active IP Right Cessation
- 1998-09-17 WO PCT/US1998/019419 patent/WO1999013886A1/en not_active Application Discontinuation
- 1998-09-17 JP JP2000511506A patent/JP2003517428A/en not_active Withdrawn
- 1998-09-17 KR KR1020007002879A patent/KR20010030622A/en not_active Application Discontinuation
- 1998-09-17 IL IL13514098A patent/IL135140A0/en unknown
- 1998-09-17 AU AU93951/98A patent/AU752531B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040266A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for asthma |
WO1996040162A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for lung diseases using antisense oligonucleotides |
Non-Patent Citations (3)
Title |
---|
NYCE J W ET AL: "DNA ANTISENSE THERAPY FOR ASTHMA IN AN ANIMAL MODEL", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 385, 20 February 1997 (1997-02-20), pages 727 - 725, XP000891493, ISSN: 0028-0836 * |
NYCE J W: "Insight into adenosine receptor function using antisense and gene-knockout approaches", TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 20, no. 2, February 1999 (1999-02-01), pages 79 - 83, XP004157301, ISSN: 0165-6147 * |
See also references of WO9913886A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1019065A1 (en) | 2000-07-19 |
BR9812650A (en) | 2000-08-22 |
IL135140A0 (en) | 2001-05-20 |
AU9395198A (en) | 1999-04-05 |
WO1999013886A1 (en) | 1999-03-25 |
WO1999013886B1 (en) | 1999-04-22 |
CA2304312A1 (en) | 1999-03-25 |
AU752531B2 (en) | 2002-09-19 |
KR20010030622A (en) | 2001-04-16 |
JP2003517428A (en) | 2003-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL135140A0 (en) | Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications | |
AU1581895A (en) | Nucleic acid-containing composition, its preparation and use | |
IL123393A0 (en) | Pesticide compositions comprising redispersible polymers | |
AU2224899A (en) | Antimicrobial nail coating composition | |
AU8680698A (en) | Polynucleotide compositions | |
IL130777A (en) | 3-heterocyclyl-substituted benzoyl derivatives, their preparation and compositions comprising them | |
IL142736A0 (en) | Transcriptional activator lec 1 nucleic acids, polypeptides and their uses | |
AU6018399A (en) | Plant glutamine: fructose-6-phosphate amidotransferase nucleic acids | |
HUP0102372A3 (en) | Dihydropyrimidines, preparation thereof and pharmaceutical compositions containing the same | |
AU2215995A (en) | Freeze-dried compositions comprising rna | |
AU5254098A (en) | Conditioning shampoo compositions | |
AU1383699A (en) | Coating composition | |
AU1119399A (en) | Microorganism genomics, compositions and methods related thereto | |
AU5203098A (en) | Nail enamel composition | |
ZA974081B (en) | Nail enamel compositions. | |
AU4230297A (en) | Hair conditioning compositions | |
AU5695198A (en) | Nail enamel composition | |
AU3698297A (en) | Compositions containing at least one nucleic acid and their applications in the biomedical field, particularly in gene therapy | |
EP1374894A3 (en) | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof | |
PL342045A1 (en) | 2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases | |
AU5032298A (en) | Coating compositions | |
AU2710400A (en) | Monocyte-derived nucleic acids and related compositions and methods | |
AU6113598A (en) | Anti-corrosive pigments | |
AU4724799A (en) | Compositions comprising endotoxin neutralizing protein and derivatives and uses thereof | |
AU2071897A (en) | Hair conditioning compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000316 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020107 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050401 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1029522 Country of ref document: HK |